Please select your page
Home
About CERENIS
Management
Board of Directors
Steering Committee
Scientific Advisory Board
Specialized Committees
Audit Committee
Remuneration Committee
Research Committee
Scientific Advisory Board in Oncology
Our approach
About HDL and CVD
The commercial opportunity
The science of HDL
HDL deficiency
What is HDL deficiency?
Our therapies
CER 001
CER 209
Scientific presentation
Media
Press releases
Events
Investors
Regulated information
Shareholder meeting
Investor presentations
Corporate presentation
Cerenis on stock market
Investor Contacts
Financial Calendar
Please select your page
Home
About CERENIS
— Management
— Board of Directors
— Steering Committee
— Scientific Advisory Board
— Specialized Committees
—— Audit Committee
—— Remuneration Committee
—— Research Committee
— Scientific Advisory Board in Oncology
Our approach
— About HDL and CVD
— The commercial opportunity
— The science of HDL
HDL deficiency
— What is HDL deficiency?
Our therapies
— CER 001
— CER 209
— Scientific presentation
Media
— Press releases
— Events
Investors
— Regulated information
— Shareholder meeting
— Investor presentations
— Corporate presentation
— Cerenis on stock market
— Investor Contacts
— Financial Calendar
Press releases
Events
Press releases
13/05/2015
Cash position and revenue for Q1 2015
25/03/2015
Outstanding success of Cerenis Therapeutics’ IPO with €53.4 million raised on Euronext Paris
12/03/2015
CERENIS THERAPEUTICS launches its IPO on the Euronext regulated market in Paris
09/02/2015
CERENIS THERAPEUTICS announces the appointment of a new Director of Clinical Research and new members to the Board
03/09/2014
CERENIS THERAPEUTICS receives EMA Orphan Drug Designations for CER-001 for the treatment of ApoA-I and ABCA-1 deficiencies
03/09/2014
CERENIS THERAPEUTICS appoints R. Pasternak as Chairman of Cerenis Board September 3, 2014
02/06/2014
CERENIS THERAPEUTICS reports two positive Phase II Studies for HDL mimetic CER-001 at EA
Page 4 of 4
Start
«
1
2
3
4
Contact
Scroll
